닥플 플러스
제15차 International Congress on Lipid & Atherosclerosis (ICoLA 2026) 1일차
한국지질ㆍ동맥경화학회
연수평점 :3점
오프라인
주관
한국지질ㆍ동맥경화학회
교육일자
2026-09-10
수강료
140,000원
교육형태
오프라인
등록일시
2026-07-24
교육시간
17시간 40분
연수평점
3점
장소
서울특별시 콘래드 서울 호텔(그랜드볼룸1~3, 파크볼룸3)
교육종류
내과
타임테이블
| 날짜 | 시간 | 강의명 | 강사 | 구분 |
|---|---|---|---|---|
| 2026-09-10 | 13:00~13:18 | LDL (Low-Density Lipoprotein) versus inflammation: what remains after aggressive lipid lowering? | Oh-sung Kwon(The Catholic University of Korea Republic of Korea) | - |
| 2026-09-10 | 13:18~13:36 | Emerging anti-inflammatory therapies in ASCVD (Atherosclerotic Cardiovascular Disease): canakinumab, NLRP3 (NOD-, LRR-, and pyrin domain-containing protein 3) inhibitors, and beyond | Sung-A Bae(Yonsei University Republic of Korea) | - |
| 2026-09-10 | 13:36~13:54 | Colchicine for secondary prevention in ASCVD (Atherosclerotic Cardiovascular Disease) | Dae Young Cheon(Hallym University Republic of Korea) | - |
| 2026-09-10 | 13:54~14:12 | Immune Mechanisms of Residual Cardiovascular Risk: From Oxidation-Specific Epitopes to Therapeutic Targets | Christoph J. Binder(Medical University of Vienna Austria) | - |
| 2026-09-10 | 14:12~14:30 | Discussion | - | - |
| 2026-09-10 | 14:30~14:40 | Break | - | - |
| 2026-09-10 | 14:40~14:58 | Refined risk assessment in FH (Familial Hypercholesterolemia) | Sayaka Funahashi(Kyorin University Japan) | - |
| 2026-09-10 | 14:58~15:02 | Q&A | - | - |
| 2026-09-10 | 15:02~15:20 | Cause of death in FH (Familial Hypercholesterolemia) | Chan Joo Lee(Yonsei University Republic of Korea) | - |
| 2026-09-10 | 15:20~15:24 | Q&A | - | - |
| 2026-09-10 | 15:24~15:42 | Experience on new drugs for FH (Familial Hypercholesterolemia): including lomitapide & evinacumab | Hayato Tada(Kanazawa University Japan) | - |
| 2026-09-10 | 15:42~15:46 | Q&A | - | - |
| 2026-09-10 | 15:46~16:04 | Gene editing in dyslipidemia | Hyong Bum Kim(Yonsei University Republic of Korea) | - |
| 2026-09-10 | 16:04~16:08 | Q&A | - | - |
| 2026-09-10 | 16:10~16:20 | Break | - | - |
| 2026-09-10 | 16:20~16:38 | Do East Asians need lower statin intensity? Ethnic differences in LDL-C (Low-Density Lipoprotein Cholesterol) response and safety | Eun Jeong Cho(Chung-Ang University Republic of Korea) | - |
| 2026-09-10 | 16:38~16:56 | Why TG (Triglycerides) is important in Asians? | Daisaku Masuda(Rinku General Medical Center Japan) | - |
| 2026-09-10 | 16:56~17:14 | Clinical/genetic features of severe Hypertriglyceridemia in Korea | Hun Jee Choe(Hallym University Republic of Korea) | - |
| 2026-09-10 | 17:14~17:32 | Chylomicronemia: Past, Present, and Future | Hiroaki Okazaki(Teikyo University Japan) | - |
| 2026-09-10 | 17:32~17:50 | Discussion | - | - |
| 2026-09-10 | 13:00~13:20 | Dietary Modulation of Microbial Lipid Metabolites and Innate Immunity in Atherosclerosis | Eun-Kyeong Jo(Chungnam National University Republic of Korea) | - |
| 2026-09-10 | 13:20~13:40 | Intermittent Fasting as a Nutritional Intervention to Modulate Macrophage Polarization for Vascular Health | Kyoung-Han Kim(University of Ottawa Canada) | - |
| 2026-09-10 | 13:40~14:00 | Targeting Lipid Peroxidation and Ferroptosis to Resolve Inflammation in Myocardial Ischemia-Reperfusion Injury | Su Myung Jung(Sungkyunkwan University Republic of Korea) | - |
| 2026-09-10 | 14:00~14:30 | Discussion | - | - |
| 2026-09-10 | 14:30~14:40 | Break | - | - |
| 2026-09-10 | 14:40~14:55 | (Oral presentation) Improved survival and in vivo cholesterol-lowering efficacy of microencapsulated Lactobacillus plantarum LAB12 | Ismail M. Fareez(Universiti Teknologi MARA Malaysia) | - |
| 2026-09-10 | 14:55~15:10 | (Oral presentation) Lipid Accumulation Product and Visceral Adiposity Indices as Markers of Hyperuricemia and Gout: A Meta-Analysis of 575,000 patients | Khalid Sarhan(Mansoura University Hospitals Egypt) | - |
| 2026-09-10 | 15:10~15:25 | (Oral presentation) Distinct Vascular Targets of Metabolic and Kidney Dysfunction in Adults Without Advanced | Hyo-In Choi(Kangbuk Samsung Hospital Republic of Korea) | - |
| 2026-09-10 | 15:25~15:40 | (Oral presentation) A randomized, double-blind, placebo-controlled, crossover trial to comparatively evaluate the effects of magnesium hydride (MgH2) on endothelial function: a pilot study | Yasuhiro Endo(Niigata University Japan) | - |
| 2026-09-10 | 15:40~15:55 | (Oral presentation) Association of Dietary Sodium-to-Potassium Ratio with Triglyceride-Glucose Index and Metabolic Syndrome Risk in Korean Adults: Using Data from the 2022-2023 Korea National Health and Nutrition Examination Survey | Jisu Lee(Seoul Women) | - |
| 2026-09-10 | 15:55~16:10 | (Oral presentation) A Newly Developed Grain-Based Cereal Product for Glycemic Spike Management: Effects on Glycemic Index, Glycemic Load, and Postprandial Glucose Responses | Soyeon Park(Graduate School of Dong-A University Republic of Korea) | - |
| 2026-09-10 | 16:10~16:20 | Break | - | - |
| 2026-09-10 | 16:20~16:38 | Choosing the Right Combination Therapy: Statin, Ezetimibe, PCSK9 inhibitor (Proprotein Convertase Subtilisin/Kexin Type 9 inhibitor), or Beyond? | Kyung Hoon Cho(Chonnam National University Republic of Korea) | - |
| 2026-09-10 | 16:38~16:56 | Korean Fact Sheet: Current Status of LDL-C (Low-Density Lipoprotein Cholesterol) Control and Cardiovascular Risk | Ye Seul Yang(Seoul National University Republic of Korea) | - |
| 2026-09-10 | 16:56~17:14 | Korean Fact Sheet: Real-World Utilization of lipid lowering agents | Kyu Ho Kim(The Catholic University of Korea Republic of Korea) | - |
| 2026-09-10 | 17:14~17:32 | Why Are LDL-C (Low-Density Lipoprotein Cholesterol) Targets Still Unmet? Common Errors and Practical Solutions in the Clinic | Sang Yeub Lee(Chung-Ang University Republic of Korea) | - |
| 2026-09-10 | 13:00~13:20 | Biobank Resources for Human Metabolic and Vascular Research | Hyun Joung Lim(National Institute of Health Republic of Korea) | - |
| 2026-09-10 | 13:20~13:40 | Leveraging Biobank Platforms to Study Cardiometabolic Physiology and Disease | Heiko Bugger(Graz Medical University Austria) | - |
| 2026-09-10 | 13:40~14:00 | From Biobank to Multi-Omics: Integrative Analysis of Metabolic Dysfunction | Young Yang(Sookmyung University Republic of Korea) | - |
| 2026-09-10 | 14:00~14:30 | Discussion | - | - |
| 2026-09-10 | 14:30~14:40 | Break | - | - |
| 2026-09-10 | 14:40~15:00 | The Race to the Bottom: Intensive LDL-C (Low-Density Lipoprotein Cholesterol) Lowering in Very High-Risk Asian Patients | Ade Meidian Ambari(Universitas Indonesia Indonesia) | - |
| 2026-09-10 | 15:00~15:20 | Combination Therapy in High-Risk Patients: Early vs Stepwise Approach | Han Na Jung(Hallym University Republic of Korea) | - |
| 2026-09-10 | 15:20~15:40 | Practical Approaches to Statin Intolerance: From Clinical Trials to Real-World Solutions | Jung-Joon Cha(Korea University Republic of Korea) | - |
| 2026-09-10 | 15:40~16:10 | Discussion | - | - |
| 2026-09-10 | 16:10~16:20 | Break | - | - |
| 2026-09-10 | 16:20~16:40 | Sex differences in lymphatic function and atherosclerosis outcomes | Catherine Martel(University of Montreal Canada) | - |
| 2026-09-10 | 16:40~17:00 | Tirzepatide and Cardiometabolic Outcomes: Implications of Dual GLP-1/GIP (Glucagon-Like Peptide-1/Glucose-Dependent Insulinotropic Polypeptide) Agonism | Yun Kyung Cho( ) | - |
| 2026-09-10 | 17:00~17:20 | Effects of SGLT2 (Sodium-Glucose Cotransporter-2) Inhibitors on Lipid Metabolism: Mechanisms and Clinical Implications | Joon Hwa Hong(Eulji University Republic of Korea) | - |
| 2026-09-10 | 17:20~17:50 | Discussion | - | - |
| 2026-09-10 | 13:00~13:20 | Arterial Tissue Gene Expression Associated With Telomere Length Attrition in Coronary Artery Disease | Rajkumar Dorajoo(National University of Singapore Singapore) | - |
| 2026-09-10 | 13:20~13:40 | Factor XI Deficiency in Apolipoprotein E/Factor XI Double-Knockout Mice Decreases Atherosclerosis by Lowering MSR1(Macrophage Scavenger Receptor 1) mRNA(messenger RNA) Expression Within the Plaque | Ophira Salomon(Tel-Aviv University Israel) | - |
| 2026-09-10 | 13:40~14:00 | Administration of Sodium-Glucose Cotransporter-2 Inhibitors Following Acute Myocardial Infarction: A Systematic Review, Meta-Analysis, and Meta-Regression of Randomized Trials | Timotius Ivan Hariyanto(Pelita Harapan University Indonesia) | - |
| 2026-09-10 | 14:00~14:30 | Discussion | - | - |
| 2026-09-10 | 14:30~14:40 | Break | - | - |
| 2026-09-10 | 14:40~15:00 | GLP-1 RA (Glucagon-Like Peptide-1 Receptor Agonist) for stroke prevention | Kang-Ho Choi(Chonnam National University Republic of Korea) | - |
| 2026-09-10 | 15:00~15:20 | SGLT2 inhibitor (Sodium-Glucose Cotransporter-2 inhibitor) for stroke survivors | Jeong-Min Kim(Seoul National University Republic of Korea) | - |
| 2026-09-10 | 15:20~15:40 | SGLT2 inhibitor (Sodium-Glucose Cotransporter-2 inhibitor) or GLP-1 RA (Glucagon-Like Peptide-1 Receptor Agonist) for cognitive disorder | Sang-Won Han(Soonchunhyang University Republic of Korea) | - |
| 2026-09-10 | 15:40~16:10 | Discussion | - | - |
| 2026-09-10 | 16:10~16:20 | Break | - | - |
| 2026-09-10 | 16:20~16:40 | Lipid abnormalities in CKD (Chronic Kidney Disease) | Hong Sang Choi(Chonnam National University Republic of Korea) | - |
| 2026-09-10 | 16:40~17:00 | Why patients with CKD (Chronic Kidney Disease) develop accelerated atherosclerosis | Cheol Ho Park(Yonsei University Republic of Korea) | - |
| 2026-09-10 | 17:00~17:20 | Cardiovascular prevention in CKD (Chronic Kidney Disease) patients | Eun Roh(Seoul National University Republic of Korea) | - |
| 2026-09-10 | 17:20~17:50 | Discussion | - | - |
비고
-교수, 봉직의, 개원의 : 조기 등록 80,000원/100,000원 / 사전 등록 100,000원/120,000원 / 현장 등록 120,000원/140,000원-전임의, 전공의, 군의관/공보의, 연구원, 간호사, 영양사, 약사, 기업회원, 기타 : 조기 등록 50,000원 / 사전 등록 60,000원 / 현장 등록 70,000
문의처
담당자
ICoLA 준비사무국
연락처
02-6958-7061
이메일
lipid@planbear.co.kr